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Abstract A single mutation within the transmembrane region
of the Neu receptor (Val664CGlu) is known to enhance tyrosine
kinase activity, by promoting receptor dimerization. In order to
gain insight into potential structural changes that arise as a
result of the mutation, peptides corresponding to the complete
transmembrane domain of proto-oncogenic and mutant forms of
Neu have been studied by 1H nuclear magnetic resonance in the
solvent tri£uoroethanol (TFE). The chemical shifts are similar
for both forms of the peptide, with the exception of amide
residues close to the mutation site. Both peptides adopt a helical
conformation, with a distinct bend one turn downstream of the
mutation site. This deformation gives rise to several nuclear
Overhauser e¡ects, the majority of which were detected in
both peptides, that are atypical for a straight canonical K-helix.
Our data in this solvent do not support a conformational change
in the transmembrane domain of monomeric Neu as a result of
the mutation. Sodium dodecyl sulfate^polyacrylamide gel elec-
trophoresis analysis indicates that proto-oncogenic Neu peptides
have a higher propensity to oligomerize in the solvent TFE than
the Glu664 oncogenic form.
1 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The catalytic activation of many receptor tyrosine kinases
(RTKs) occurs following dimerization, leading to the phos-
phorylation of intracellular substrates [1,2]. RTKs initiate
growth and di¡erentiation pathways, and their level of activ-
ity is predominantly in£uenced by the binding of cognate
growth factors. In some instances however, a mutation within
the transmembrane domain of these receptors promotes di-
merization, and subsequent kinase activity in the absence of
ligand binding [3^6].
One example of modulated activity resulting from a muta-
tion in the transmembrane domain of a tyrosine kinase recep-
tor occurs in Neu/ErbB-2, a member of the epidermal growth
factor receptor (EGFR) subfamily. The replacement of a va-
line residue at position 664 of Neu with glutamic acid has
been shown to increase receptor dimerization and kinase ac-
tivity [7^9], and leads to a transforming phenotype in some
cell lines [10].
As yet, there is no indisputable formulation to explain the
physical basis for enhanced receptor dimerization and activity
upon mutation. One theory provides that enhanced receptor
interaction occurs as a result of inter-receptor hydrogen bond-
ing involving the side chain carboxyl group of glutamic acid
[11]. This has been postulated to occur via symmetrical biden-
tate hydrogen bonds between the glutamate side chains of
adjacent receptors [12], or alternatively, between the side
chain of one receptor and the amide backbone of another
[13,14]. Another theory, not incompatible with the former,
favors a structural reorientation of the transmembrane do-
main upon mutation, that facilitates inter-helical dimeric in-
teractions. Wide-line 2H nuclear magnetic resonance (NMR)
spectral di¡erences between monomeric forms of proto-onco-
genic and mutant Neu/ErbB-2 peptides in bilayers have been
observed, and are largely dependent on the position of the 2H
probe within the transmembrane region [15,16]. Probes up-
stream of the mutation site exhibited similar splitting patterns,
while the probes close to and downstream of the mutation site
had noticeably di¡erent quadrupolar splitting. These results
were ascribed to limited structural di¡erences between the two
forms of the peptide.
Results of theoretical studies on the Neu/ErbB-2 transmem-
brane domain have illuminated potential structural changes
that might arise due to the transforming mutation. Using
conformational energy analysis, Brandt-Rauf et al. [17,18]
have predicted that the favored conformation of the proto-
oncogenic receptor would exhibit a sharp bend at the muta-
tion site, whereas a straight K-helical conformation would be
favored for the mutant. In a separate study, Z-bulge distor-
tions due to backbone hydrogen bond rearrangements were
observed in molecular dynamics (MD) simulations of the
ErbB-2 transmembrane domain performed in vacuo [19],
and might be favored in proto-oncogenic peptides over mu-
tated ones.
There have been two reported studies on the structure of
peptides corresponding to the transmembrane domain of Neu
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in the solvent tri£uoroethanol (TFE). Gullick et al. [20] syn-
thesized 18 residue peptides representing a portion of the
transmembrane region, with some hydrophobic residues re-
placed with serine. Both peptides adopted a straight canonical
helical structure, and there was no discernible conformational
change observed between proto-oncogenic and mutant forms
of the peptides. The structure of a 35 residue peptide corre-
sponding to the entire transmembrane domain of proto-onco-
genic Neu has been reported by Goetz et al. [21]. They re-
ported a seven residue Z-bulge distortion, downstream of the
mutation site, centered around four consecutive valine resi-
dues (Val673^Val676). This distortion was similar to that seen
in MD simulations [19,22]. In this study, no results were re-
ported for the mutant form of the transmembrane domain.
We have initiated NMR studies on transmembrane Neu
peptides, in order to establish potential structural and/or dy-
namic changes that arise as a result of the transforming mu-
tation. In this investigation, we report NMR-derived struc-
tures in TFE, for two chemically synthesized peptides that
incorporate the putative transmembrane domain of both pro-
to-oncogenic and mutant receptors. The proton chemical
shifts and nuclear Overhauser e¡ect (NOE) connectivities
for both molecules are similar, and consistent with an K-heli-
cal structure. We detected a £exible region in the two pep-
tides, which gave rise to a distinct bend in the conformation
roughly one helical turn downstream of the mutation site. To
assess their level of aggregation following TFE exposure, the
peptides were analyzed using sodium dodecyl sulfate^polyac-
rylamide gel electrophoresis (SDS^PAGE), which indicates
that proto-oncogenic Neu peptides form higher order aggre-
gates more readily in this solvent than the mutant peptides.
2. Materials and methods
2.1. Peptide synthesis
Peptides of 36 amino acids, comprising residues adjacent to and
including the putative transmembrane domain of proto-oncogenic
and mutant Neu, were synthesized using the FMOC strategy, and
puri¢ed by reversed-phase chromatography. The purity of the pep-
tides was con¢rmed by mass spectrometry.
The sequence of the proto-oncogenic peptide, corresponding to the
position of the amino acids within the Neu receptor, is: Q651RASP-
VTFIIATVV664GVLLFLILVVVVGILIKRRRQK686. The mutant
peptide has an identical sequence, except at position 664, where valine
is replaced with glutamic acid. Within our peptides the mutation site
corresponds to residue 14.
2.2. NMR spectroscopy and structure determination
Approximately 1.5 mg of puri¢ed peptide was dissolved in 0.5 ml of
d2-TFE (Cambridge Isotope Laboratories), to give a concentration of
V1.5 mM. 2D-Homonuclear correlation spectra were acquired at 303
K, on a Bruker Avance spectrometer operating at 600 MHz, with a
spectral window of 10.1 ppm. Chemical shifts were referenced with
respect to the residual methylene protons of TFE, appearing at 3.88
ppm. NOESY spectra, with mixing times of 150, 200 and 300 ms,
were acquired using a presaturation pulse during the relaxation delay
to suppress the OH resonance of TFE, and using time-proportional
phase increment for quadrature detection. Scalar coupled networks
were assigned with total correlation spectroscopy (TOCSY) spectra
acquired using a decoupling in the presence of scalar interactions
(DIPSI)-2 [23] pulse scheme, isotropic mixing times of 30, 60, and
75 ms, solvent suppression using WATERGATE [24], and an echo^
antiecho phase cycle for quadrature detection. All 2D spectra were
acquired with 2048 data points in the direct dimension, 256 points in
the indirect dimension, and 256 scans per increment.
NMR data were processed using the software Felix97 (Biosym), on
an O2 workstation (Silicon Graphics). Shifted sine-bell (90‡) window
functions were applied to the transients prior to Fourier transforma-
tion. The ¢nal matrix size was 2048U512, corresponding to a digital
resolution of 2.9 Hz/point in the direct dimension, and 11.7 Hz/point
in the indirect dimension.
NOE distance restraints were obtained from integrated cross-peaks
obtained from NOESY spectra with mixing times of 300 ms. Based on
peak volumes, NOEs were classi¢ed as either ‘strong’, ‘medium’, or
‘weak’, corresponding to restraint distances of 6 3.5, 6 4.5, and
6 6.0 AR respectively. In all cases, a lower bound distance restraint
of 2.0 AR was applied. Correction factors for pseudoatoms were added
to these limits as described by Wu«thrich et al. [25]. The calculation of
energy-minimized structures was carried out using the program X-
PLOR [26]. One hundred embedded substructures were generated
and regularized by simulated annealing [27], with an initial temper-
ature of 3000 K, using 2000 high temperature cycles of restrained
energy minimization followed by 3 ps restrained molecular Verlet
dynamics. Two thousand cooling steps were performed to a ¢nal
temperature of 300 K. During cooling, the van der Waals interactions
were increased by varying the van der Waals repel function from
0.003 to 4 kcal/mol/AR 4. Structures obtained from simulated annealing
were further re¢ned [28] through 10 000 cycles of restrained energy
minimization. A square-well restraining function was used for the
e¡ective NOE energy term. During all calculations, side chain groups
were uncharged. Twenty-two structures with the lowest energy and
without NOE violations s 0.1 AR were chosen for further analysis.
2.3. Gel electrophoresis
Peptides were dissolved in standard loading bu¡er [29], incubated at
42‡C for 30 min, and run on a 16.5% Tris-tricine gel [30]. The gel was
stained with Coomassie brilliant blue. Peptides pretreated with TFE
were incubated for 1 h at room temperature, and the TFE was evapo-
rated under a steady stream of N2.
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Fig. 1. TOCSY spectra corresponding to the NH^CHK region of
Neu peptides. Spectra are of (A) proto-oncogenic and (B) mutant
peptide in TFE at 30‡C, with the NH-CHK cross-peaks labeled.
Some of the amide proton chemical shifts di¡er between the two
peptides for residues within 1.5 helical turns of mutation site, where-
as the CHK chemical shift does not change signi¢cantly for any resi-
due.
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3. Results
Standard homonuclear correlation experiments were used
to assign the resonances of both proto-oncogenic and mutant
Neu peptides, and to obtain restraint distances for the calcu-
lation of their average structure in TFE. All of the NMR
experiments were performed at peptide concentrations of 1.5
mM. Circular dichroism experiments on proto-oncogenic Neu
peptides in this solvent [21] have indicated that there is min-
imal dimerization at concentrations less than 2 mM. The NH-
CHK region of a TOCSY spectrum of both peptides is pre-
sented in Fig. 1. The majority of the cross-peaks for both
peptides appear at the same chemical shift, with the exception
of amide resonances within 1.5 helical turns of the mutation
site. There is very little di¡erence in the CHK chemical shifts
for both peptides, and they are up¢eld of random coil values,
indicating the residues are participants in an K-helix [31].
As indicated in Fig. 2, the NOE connectivity pattern for
both peptides is typical of an K-helix, with several strong HKi^
HLiþ3 and HKi^NHiþ3 contacts for residues between 5 and 32.
The pattern observed for each peptide is not identical. This is
due in part to the movement of some amide resonances in the
spectra, which caused the overlap of resonances in some re-
gions of the NOESY spectra for one peptide, and not the
other. This resulted in a slightly di¡erent complement of un-
ambiguous NOE assignments for the two peptides. Also, res-
idues at the C-terminus of the proto-oncogenic peptide yielded
fewer NOEs than the analogous portion of the mutant pep-
tide. Therefore, there was slightly poorer precision in the aver-
age structure derived for the proto-oncogenic peptide (as in-
dicated by the root mean square (r.m.s.) values in Table 1).
Several NOEs, depicted in the lower portion of Fig. 2
(NHi^NHiþ4, KHi^LHiþ4, NHi^KHiþ5), are indicative of a
deviation from a straight canonical K-helix. Most were de-
tected in both peptides, and appear roughly one helical turn
downstream of the mutation site. These NOEs are indicative
of a helical deformation, and give rise to a bend in the con-
formation of both peptides.
A total of 336 experimental distance restraints were used to
deduce the conformation of the proto-oncogenic peptide, and
368 were used for the mutant peptide (Table 1). These calcu-
lations were performed using the program X-PLOR [26].
From an initial pool of 100 structures generated through sim-
ulated annealing, a family of 22 was selected for the calcula-
tion of the average conformation of each peptide. These struc-
tures had the lowest overall energy, and no NOE violations
greater than 0.1 AR . The superposition of the structures (Fig. 3)
displays good precision, with r.m.s. deviations for backbone
atoms of 1.38 and 1.25 AR for the proto-oncogenic and mutant
peptides respectively. The ¢nal conformation of each peptide,
shown in Fig. 3, was calculated based on the atoms of resi-
dues 5^32 averaged over the 22 structures in the family.
NMR experiments were performed at concentrations where
peptide aggregation is believed to be minimal. Using SDS^
PAGE, we also monitored whether there was evidence of ag-
gregation upon exposure to TFE, followed by solvent evapo-
ration ^ since studies in bilayers with peptides of this nature
often involve solubilization in TFE before reconstitution. The
peptides were exposed to either an H2O/acetonitrile mixture
containing 0.1% tri£uoroacetic acid, where they are unfolded,
or TFE, prior to incubation in standard SDS loading bu¡er.
The interpretation of the migration pattern of transmembrane
K-helices on polyacrylamide gels is complicated by the obser-
vation that these peptides tend to migrate at rates faster than
Fig. 2. NOE connectivities for Neu peptides. NOEs are shown as a
function of the amino acid sequence for the proto-oncogenic (black
lines) and mutant (gray lines) peptides, with the intensity of the
NOE re£ected by the line thickness.
Table 1
Structural statistics for proto-oncogenic and mutant Neu peptides
Proto-oncogenic Mutant
Total experimental restraints 336 368
Intraresidual 133 134
Sequential 203 234
Number of structures used to determine average 22 22
Number of structures with restraint violations s 0.1 AR 0 0
r.m.s. deviations (AR ) to the average structure from residues 5^32:
backbone atoms (N, CK, Ca) 1.38 1.25
heavy atoms 1.89 1.76
all atoms 1.96 1.87
Ramachandran plot statistics for residues 5^32:
Number of residues in most favored regions 27 26
Number of residues in additional allowed regions 3 3
Number of residues in generously allowed regions 0 1
Number of residues in disallowed regions 0 0
FEBS 26896 20-1-03
R.S. Houliston et al./FEBS Letters 535 (2003) 39^43 41
would be expected for a protein/peptide of similar mass [32].
Nonetheless, our results clearly demonstrate a di¡ering migra-
tion pattern for the two peptides both before and after treat-
ment with TFE, based on the extent of oligomerization (Fig.
4). Proto-oncogenic peptide, unfolded prior to incubation in
the SDS bu¡er, runs as a single band on the gel, at roughly
1.5U its mass. Following TFE treatment, the peptide runs as
a di¡use band containing higher order aggregates. The mutant
peptide migrates predominantly at 1.0U its mass before and
after TFE treatment, with a faint band appearing at 2.0U its
mass.
4. Discussion
Elucidating the details of structural changes resulting from
a point mutation in the Neu/ErbB-2 receptor may provide
important insight into the activation mechanism of RTKs.
Towards this end, several theoretical and experimental inves-
tigations on the transmembrane region of this receptor have
been reported.
Smith et al. [12] determined that the glutamate side chains
of mutant Neu oligomers reconstituted in bilayers were pro-
tonated and participants in a hydrogen bond, which could
potentially stabilize dimeric interactions between receptors.
2H NMR spectral di¡erences have been observed between
proto-oncogenic and mutant forms of Neu/ErbB-2 receptors
in bilayers, and have been attributed to structural di¡erences
close to and downstream of the mutation site [15,16]. Con-
formational energy analysis predicted a bend in proto-onco-
genic Neu peptides at the mutation site, which would hinder
side-to-side association of the transmembrane domain ^ as
opposed to the straight helical structure predicted for the mu-
tant form [17,18]. MD simulations performed on ErbB-2 pep-
tides in vacuo have exhibited Z-bulge distortions [19,22]. Z-
bulges, also referred to as ‘K aneurisms’, have been observed
experimentally in helices of several globular proteins [33^35].
A transition from an K- to a Z-helix could alter the relative
orientation of side chains of a helical face, which in turn could
signi¢cantly impact the side-to-side interaction of adjacent
helices.
Based on our studies of Neu peptides in TFE, the confor-
mation of the transmembrane domain of this receptor does
not change as a result of the transforming mutation. This is
supported by the agreement between the proton chemical
shifts in both peptides, and by the similarity in their struc-
tures. Careful inspection of our spectra did reveal several
NOEs that were indicative of a deviation from a straight he-
lical conformation. Our resulting structures exhibited a dis-
tinct bend one turn downstream of the mutation site. The
structure of a 35 residue proto-oncogenic Neu peptide in
TFE was reported to contain a Z-bulge downstream of the
mutation site, spanning residues Ile671 to Gly677 [21], however
no results were reported for the mutant form of the receptor.
It is unclear why we did not see a Z-bulge distortion in the
proto-oncogenic form of the peptide. Goetz et al. [21] noted
two NOEs that were indicative of a deviation from a standard
canonical K-helix, speci¢cally two NHi^KHiþ5 NOEs. We ob-
served one NHi^KHiþ5 NOE (Ile671 to Val676) in the proto-
oncogenic form of the peptide. No NHi^KHiþ5 NOEs could
be con¢rmed in the mutant form of the peptide. The methods
used to calculate the structures di¡ered as well ; we used X-
PLOR, which makes use of CHARMM force ¢elds, whereas
Goetz et al. used DYANA [36], which employs AMBER force
¢elds.
A recent investigation using Escherichia coli cell membranes
quanti¢ed the dimerization of constructs containing trans-
membrane domains from members of the EGFR family,
A B
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Fig. 3. Solution structure of Neu peptides in TFE. Displayed are
the families of 22 structures for the (A) proto-oncogenic and (B)
mutant forms of the peptide selected for the computation of the
average conformation. These structures had no NOE violations
greater than 0.1 AR , and had the lowest energy among those gener-
ated by simulated annealing. The ribbon representations of the (C)
proto-oncogenic and (D) mutant Neu peptides are based on atoms
in residues 5^32, averaged over the 22 structures. The ¢gure was
produced using the program MOLMOL [38].
1 2 3 4 5
Fig. 4. SDS^PAGE analysis of Neu peptides. The lanes of the gel
contain the proto-oncogenic form prior to (2) and following TFE
treatment (3), and the mutant form prior to (4) and following TFE
treatment (5). Standard molecular weight markers are in lane 1 la-
beled with their corresponding molecular mass (kDa). Monomeric
forms of both Neu peptides have a molecular mass of V4 kDa.
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and demonstrated that, in contrast with other studies of full
length receptors, constructs containing the proto-oncogenic
form of the ErbB-2 transmembrane domain oligomerized
more readily than those containing the mutant form [37].
SDS^PAGE analysis of our chemically synthesized Neu trans-
membrane peptides indicates that the proto-oncogenic form
aggregates more readily than the mutant form upon exposure
to TFE. Clearly, the extent to which these peptides will oligo-
merize under various conditions cannot be predicted based on
studies with full length receptors. The propensity of these
molecules to dimerize may be dictated by elements in the
extra- and intracellular domains in addition to the transmem-
brane region.
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